Uptake, feasibility, cost and cost effectiveness of universal screening for gestational diabetes mellitus in primary care

Conditions

Gestational diabetes mellitus Pregnancy and Childbirth Diabetes mellitus arising in pregnancy

Tierney M, O'Dea A, Danyliv A, Glynn LG, McGuire BE, Carmody LA, Newell J, Dunne FP.

2015-08-0514 citations

Screening uptake rates and the clinical and cost effectiveness of screening for gestational diabetes mellitus in primary versus secondary care: study protocol for a randomised controlled trial

Angela O’Dea, Jennifer J. Infanti, Paddy Gillespie, Olga Tummon, Samuel Fanous et al. (9 authors)

Trials2014-01-1711 citations

10.1186/1745-6215-15-27

Interventions

The target population for the study includes all women, ordinarily resident in the Galway University Hospitals (GUH) catchment area, who present with pregnancy . Following recruitment, eligible women

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women who present with pregnancy at the maternity clinic at Galway University Hospitals (GUH)

Exclusion criteria

Exclusion criteria: Pregnant women with pre-diagnosed diabetes or pre-diagnosed gestational diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Uptake of screening offer	—

Secondary

Measure	Time frame
1. GDM prevalence 2. Timing of screening 3. Access to antenatal diabetes care for women with GDM 4. Pregnancy Outcomes for women with GDM: 4.1. Maternal Outcomes: mode of delivery [vaginal delivery (normal or assisted), caesarean section (emergency or elective)), hypertensive, disorders of pregnancy (gestational hypertension and pre-eclampsia), polyhydramnios, and ante and postpartum haemorrhage. 4.2. Neonatal Outcomes: live birth rate, congenital malformation rate; premature delivery (defined as delivery before 37 weeks gestation); birthweight; macrosomia (defined as birthweight >4 kg); large for gestational age; small for gestational age; admission to neonatal intensive care unit; duration of stay in neonatal intensive care unit; Apgar score at 5 min; shoulder dystocia; neonatal hypoglycaemia; neonatal jaundice; and neonatal respiratory distress 5. Economic Outcomes: 5.1. Costs of Care 5.2. Quality Adjusted Life Years (QALYs) 5.3. Incremental Cost per QALY gained	—

Measure

Time frame

1. GDM prevalence 2. Timing of screening 3. Access to antenatal diabetes care for women with GDM 4. Pregnancy Outcomes for women with GDM: 4.1. Maternal Outcomes: mode of delivery [vaginal delivery (normal or assisted), caesarean section (emergency or elective)), hypertensive, disorders of pregnancy (gestational hypertension and pre-eclampsia), polyhydramnios, and ante and postpartum haemorrhage. 4.2. Neonatal Outcomes: live birth rate, congenital malformation rate; premature delivery (defined as delivery before 37 weeks gestation); birthweight; macrosomia (defined as birthweight >4 kg); large for gestational age; small for gestational age; admission to neonatal intensive care unit; duration of stay in neonatal intensive care unit; Apgar score at 5 min; shoulder dystocia; neonatal hypoglycaemia; neonatal jaundice; and neonatal respiratory distress 5. Economic Outcomes: 5.1. Costs of Care 5.2. Quality Adjusted Life Years (QALYs) 5.3. Incremental Cost per QALY gained

—

Countries

Ireland

Outcome results

None listed